Next Article in Journal
Characterization of the Asiatic Acid Glucosyltransferase, UGT73AH1, Involved in Asiaticoside Biosynthesis in Centella asiatica (L.) Urban
Next Article in Special Issue
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Previous Article in Journal
Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents
Previous Article in Special Issue
Targeting Immune Cell Checkpoints during Sepsis
Open AccessReview

Immunotherapy for Prostate Cancer: Where We Are Headed

1
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
2
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
3
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy
4
Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
5
Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
6
Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
7
Urology Unit, Forlì Hospital, Romagna Local Health Service, 47100 Forlì, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2627; https://doi.org/10.3390/ijms18122627
Received: 22 October 2017 / Revised: 27 November 2017 / Accepted: 2 December 2017 / Published: 5 December 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients. View Full-Text
Keywords: prostate cancer; immunotherapy; vaccines; CTLA4; PD1; PD-L1; antibodies prostate cancer; immunotherapy; vaccines; CTLA4; PD1; PD-L1; antibodies
Show Figures

Graphical abstract

MDPI and ACS Style

Schepisi, G.; Farolfi, A.; Conteduca, V.; Martignano, F.; De Lisi, D.; Ravaglia, G.; Rossi, L.; Menna, C.; Bellia, S.R.; Barone, D.; Gunelli, R.; De Giorgi, U. Immunotherapy for Prostate Cancer: Where We Are Headed. Int. J. Mol. Sci. 2017, 18, 2627.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop